Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharmasum Therapeutics
Profiles of AdverseEvents, AventaMed, Ensysce Biosciences, Jounce Therapeutics, LensGen, Marvao Medical Devices, Pharmasum Therapeutics, and Rotation Medical.
Most individuals with Down syndrome who live long enough will develop Alzheimer’s disease, and Pharmasum Therapeutics AS hopes to develop an AD program by targeting a protein kinase that may underlie that association. The company intends to develop agents to treat AD in individuals with DS, a large and growing market, and potentially all other patients afflicted with Alzheimer’s.
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.